NUVL – nuvalent, inc. - class a (US:NASDAQ)
Stock Stats
News
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting [Yahoo! Finance]
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting
Nuvalent (NUVL) had its "buy" rating reaffirmed by HC Wainwright. They now have a $155.00 price target on the stock.
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 [Yahoo! Finance]
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
Form 4 Nuvalent, Inc. For: Apr 09 Filed by: Pelish Henry E.
Form 4 Nuvalent, Inc. For: Apr 06 Filed by: Porter James Richard
Form 8-K Nuvalent, Inc. For: Apr 07
Form 4 Nuvalent, Inc. For: Apr 01 Filed by: Balcom Alexandra
Form 4 Nuvalent, Inc. For: Apr 01 Filed by: Lane Benjamin
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.